Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $13.40 USD
Change Today +0.204 / 1.55%
Volume 107.4K
SUPN On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 9:56 AM 05/27/15 All times are local (Market data is delayed by at least 15 minutes).

supernus pharmaceuticals inc (SUPN) Snapshot

Open
$13.25
Previous Close
$13.44
Day High
$13.45
Day Low
$13.10
52 Week High
04/24/15 - $14.07
52 Week Low
10/27/14 - $7.31
Market Cap
640.0M
Average Volume 10 Days
1.0M
EPS TTM
$0.86
Shares Outstanding
47.8M
EX-Date
--
P/E TM
15.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for SUPERNUS PHARMACEUTICALS INC (SUPN)

supernus pharmaceuticals inc (SUPN) Related Bloomberg News

View More Bloomberg News

supernus pharmaceuticals inc (SUPN) Related Businessweek News

No Related Businessweek News Found

supernus pharmaceuticals inc (SUPN) Details

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its marketed products include Oxtellar XR, an extended-release oxcarbazepine and Trokendi XR, an extended-release topiramate, which are neurology products used for the treatment of epilepsy. The company products also comprise SPN-810, a molindone hydrochloride that has completed Phase II clinical trials for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which has completed Phase IIa clinical trials for the treatment of ADHD. In addition, it is developing SPN-809, a viloxazine hydrochloride as a once-daily product candidate for the treatment of depression. The company markets its products through wholesalers and pharmaceutical distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.

309 Employees
Last Reported Date: 03/12/15
Founded in 2005

supernus pharmaceuticals inc (SUPN) Top Compensated Officers

Founder, Chief Executive Officer, President, ...
Total Annual Compensation: $485.7K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $317.9K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $342.4K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $314.8K
Compensation as of Fiscal Year 2014.

supernus pharmaceuticals inc (SUPN) Key Developments

Supernus Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Reiterates Earnings Guidance for the Full Year 2015

Supernus Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, total revenue was $28,133,000 against $9,081,000 a year ago. Operating income was $3,430,000 against operating loss of $13,422,000 a year ago. Earnings before income taxes were $979,000 against loss before income taxes of $15,543,000 a year ago. Net income was $917,000 against net loss of $15,543,000 a year ago. Basic and diluted earnings per share were $0.02 against basic and diluted loss per share of $0.38 a year ago. This year over year improvement in net income is driven primarily by increased product sales associated with higher prescription volumes from Oxtellar XR and Trokendi XR. In the first quarter of 2015, net sales results were affected by changes in wholesaler inventory levels and ordering patterns. Cash flow from operations was positive in the first quarter of 2015, offset by approximately $2.5 million of legal fees associated with patent defense. For full year 2015, the company reiterated its expectation that total net product sales will grow approximately 50% as compared to 2014, ranging from $130 million to $140 million, with operating income ranging from $6 million to $10 million, driven by continued growth in product sales from both Trokendi XR and Oxtellar XR, partially offset by growth in research and development expenses.

Supernus Pharmaceuticals, Inc. to Report Q1, 2015 Results on May 05, 2015

Supernus Pharmaceuticals, Inc. announced that they will report Q1, 2015 results at 5:00 PM, US Eastern Standard Time on May 05, 2015

Supernus Pharmaceuticals, Inc., Q1 2015 Earnings Call, May 06, 2015

Supernus Pharmaceuticals, Inc., Q1 2015 Earnings Call, May 06, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SUPN:US $13.40 USD +0.20

SUPN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $60.18 USD +0.365
Cosmo Pharmaceuticals SA SFr.166.70 CHF -1.30
Depomed Inc $20.49 USD -0.10
Durect Corp $2.56 USD +0.025
Veloxis Pharmaceuticals A/S kr1.02 DKK +0.01
View Industry Companies
 

Industry Analysis

SUPN

Industry Average

Valuation SUPN Industry Range
Price/Earnings 19.1x
Price/Sales 4.2x
Price/Book 6.8x
Price/Cash Flow 17.7x
TEV/Sales 4.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUPERNUS PHARMACEUTICALS INC, please visit www.supernus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.